DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Choueiri TK. et al.
CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial.
J Clin Oncol 2017;
35: 591-597
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.